Food and Drug Administration
You’ve heard a lot of talk about the new designer drugs like K2, Bath Salts and Spice. The government has banned many of these new substances. The latest – Kratom – has many concerned.
One North Texas sweet shop owner said his average customer is not concerned about whether their donut is made with an oil containing trans fat or one that is trans fat-free, but the FDA cares and made a first time ruling concerning trans fats.
The Food and Drug Administration is recommending new restrictions on prescription medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S.
New research suggests that high levels of BPA, a chemical in many plastics and canned food linings, might raise the risk of miscarriage in women prone to that problem or having trouble getting pregnant.
Dallas County Health and Human Services announced that it has a limited amount of the Adult Safety Net Program meningitis vaccine for $10.
The results of a long-term major federal study that was done in Texas is easing worries about the safety of a hormone-blocking drug that can lower a man’s chances of developing prostate cancer.
A mother and son from Midlothian who say they were sickened at a restaurant in Lincoln, Nebraska have filed a lawsuit against the company that owns Olive Garden restaurants in a Nebraska court.
Consumers are going to know exactly what they’re getting when they buy foods labeled “gluten free.” The Food and Drug Administration is defining what the “gluten free” label really means.
Hair loss is one of chemotherapy’s most noticeable and despised side effects. Now U.S. researchers are about to put an experimental hair-preserving treatment to a rigorous test.
In a matter of weeks, the so called ‘morning-after pill’ will be made available to anyone with the money to buy it—including very young girls.
A federal judge has ruled the Food and Drug Administration must offer the so-called “morning after” pill over the counter to women of all ages regardless of age limits.
Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs.